{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:39:14Z","timestamp":1780623554838,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ozanimod, approved for the treatment of moderately to severely active ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), is a weak in vitro monoamine oxidase B (MAO-B) inhibitor. MAO-B inhibitors can cause serotonin accumulation with concomitant use of selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs). We evaluated the incidence of treatment-emergent adverse events (TEAEs) potentially associated with serotonin accumulation during ozanimod and concomitant SSRI\/SNRI use in this post hoc analysis of pooled UC studies and the open-label extension RMS DAYBREAK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data for ozanimod 0.92 mg from pooled UC studies (n\u2005=\u20051158; cutoff: January 10, 2022) and RMS DAYBREAK (n\u2005=\u20052257; cutoff: February 1, 2022) were analyzed. Concomitant SSRI\/SNRI use was allowed in the UC (n\u2005=\u200567) and RMS (n\u2005=\u2005274) studies. A narrow Medical Dictionary for Regulatory Activities search (\u201cserotonin syndrome,\u201d \u201cneuroleptic malignant syndrome,\u201d and \u201cmalignant hyperthermia\u201d) and a broad search including terms potentially associated with serotonin accumulation were conducted. The percentages of patients with TEAEs in both searches were analyzed by concomitant SSRI\/SNRI use when the TEAE occurred.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No patients had TEAEs matching the narrow search criteria. No differences were observed in the percentages of patients with \u22651 TEAE matching the broad search regardless of SSRI\/SNRI use in UC (with: 25.4% [n = 17 of 67]; without: 15.0% [n = 164 of 1091]) and RMS (with: 12.4% [n = 34 of 274]; without: 15.6% [n = 310 of 1982]) studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No evidence of increased TEAEs potentially associated with serotonin accumulation was observed with concurrent use of ozanimod and SSRIs\/SNRIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial registration<\/jats:title>\n                  <jats:p>NCT01647516, NCT02531126, NCT02435992, NCT02576717<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae136","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:35:45Z","timestamp":1721230545000},"page":"1010-1017","source":"Crossref","is-referenced-by-count":4,"title":["Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7681-8111","authenticated-orcid":false,"given":"Miguel","family":"Regueiro","sequence":"first","affiliation":[{"name":"Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-958X","authenticated-orcid":false,"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectious Diseases, and Rheumatology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Horst","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Moslin","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Charles","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnKatrin","family":"Petersen","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tatosian","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiuanlin","family":"Wu","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Lawlor","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fischer","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Academic Medical Center Amsterdam , Amsterdam ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"issue":"1","key":"2025041105234996700_CIT0001","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12888-021-03428-3","article-title":"Relationship between chronic diseases and depression: the mediating effect of pain","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"2","key":"2025041105234996700_CIT0002","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J Med Life"},{"key":"2025041105234996700_CIT0003","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in Multiple Sclerosis: a systematic review and meta-analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J Neurol Sci."},{"issue":"11","key":"2025041105234996700_CIT0004","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/ibd\/izy143","article-title":"Influences and impact of anxiety and depression in the setting of inflammatory bowel disease","volume":"24","author":"Navabi","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2025041105234996700_CIT0005","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025041105234996700_CIT0006","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/ibd\/izy235","article-title":"Increased burden of psychiatric disorders in inflammatory bowel disease","volume":"25","author":"Bernstein","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025041105234996700_CIT0007","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1176\/appi.focus.19203","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"19","author":"Garakani","year":"2021","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"2025041105234996700_CIT0008","author":"Gelenberg","year":"2010"},{"issue":"4","key":"2025041105234996700_CIT0009","doi-asserted-by":"publisher","first-page":"39576","DOI":"10.52965\/001c.39576","article-title":"Clinically relevant drug interactions with monoamine oxidase inhibitors","volume":"10","author":"Edinoff","year":"2022","journal-title":"Health Psychol Res"},{"key":"2025041105234996700_CIT0010","volume-title":"Selective Serotonin Reuptake Inhibitors","author":"Chu","year":"2022"},{"key":"2025041105234996700_CIT0011","doi-asserted-by":"publisher","first-page":"704281","DOI":"10.3389\/fcvm.2021.704281","article-title":"Antidepressant drugs effects on blood pressure","volume":"8","author":"Calvi","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"2025041105234996700_CIT0012","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1017\/S031716710001516X","article-title":"Interaction between monoamine oxidase B inhibitors and selective serotonin reuptake inhibitors","volume":"71","author":"Aboukarr","year":"2018","journal-title":"Can J Hosp Pharm."},{"issue":"1","key":"2025041105234996700_CIT0013","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bja.2019.08.010","article-title":"The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review","volume":"124","author":"Baldo","year":"2020","journal-title":"Br J Anaesth."},{"key":"2025041105234996700_CIT0014","volume-title":"Zeposia [package insert]","year":"2024"},{"key":"2025041105234996700_CIT0015","volume-title":"Zeposia [summary of product characteristics]","year":"2024"},{"issue":"11","key":"2025041105234996700_CIT0016","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol."},{"issue":"3","key":"2025041105234996700_CIT0017","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/cpdd.383","article-title":"Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT\/QTc study","volume":"7","author":"Tran","year":"2018","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"2025041105234996700_CIT0018","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/dmd.120.000220","article-title":"Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor agonist","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug Metab Dispos."},{"issue":"12","key":"2025041105234996700_CIT0019","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1007\/s12325-020-01500-0","article-title":"Multiple-dose pharmacokinetics of ozanimod and its major active metabolites and the pharmacodynamic and pharmacokinetic interactions with pseudoephedrine, a sympathomimetic agent, in healthy subjects","volume":"37","author":"Tran","year":"2020","journal-title":"Adv Ther."},{"issue":"2","key":"2025041105234996700_CIT0020","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/13524585231216854","article-title":"Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial","volume":"30","author":"Naismith","year":"2023","journal-title":"Mult Scler."},{"issue":"18","key":"2025041105234996700_CIT0021","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med."},{"issue":"7","key":"2025041105234996700_CIT0022","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"14","key":"2025041105234996700_CIT0023","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"2025041105234996700_CIT0024","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"12","key":"2025041105234996700_CIT0025","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1177\/13524585221102584","article-title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: up to 5 years of follow-up in the DAYBREAK open-label extension trial","volume":"28","author":"Cree","year":"2022","journal-title":"Mult Scler."},{"issue":"11","key":"2025041105234996700_CIT0026","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"issue":"11","key":"2025041105234996700_CIT0027","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"issue":"4","key":"2025041105234996700_CIT0028","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4196\/kjpp.2019.23.4.231","article-title":"Potency and plasma protein binding of drugs in vitro-a potentially misleading pair for predicting in vivo efficacious concentrations in humans","volume":"23","author":"Yim","year":"2019","journal-title":"Korean J Physiol Pharmacol."},{"issue":"7","key":"2025041105234996700_CIT0029","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1128\/AAC.00431-13","article-title":"In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions","volume":"57","author":"Flanagan","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"2025041105234996700_CIT0030","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ab.2016.06.025","article-title":"Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis","volume":"508","author":"Aykul","year":"2016","journal-title":"Anal Biochem."},{"issue":"5","key":"2025041105234996700_CIT0031","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/00912700122010302","article-title":"Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr","volume":"41","author":"Hendershot","year":"2001","journal-title":"J Clin Pharmacol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae136\/58575695\/izae136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/1010\/58575695\/izae136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/1010\/58575695\/izae136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:23:57Z","timestamp":1744349037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/4\/1010\/7715856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae136","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,7,17]]}}}